Abstract 1676P
Background
Breast cancer (BC) survivors face many problems regarding sex. A range of medical treatments targeted to breast cancer patients leave behind large side effects that can negatively influence their sex life and change their body image, their self-esteem and their confidence. Most Tunisian Breast cancer survivors are reluctant to discuss their sexual problems with their doctors. Thus, their troubled sex life remains hidden. The aim of our study was to identify those sexual difficulties and to address the problems our patients are facing.
Methods
Patients diagnosed and treated for BC at the medical oncology department with active sex life prior to diagnosis were asked to complete a questionnaire from January to March 2023. The survey’s aim is to highlight the underlying problems breast cancer survivors are confronting and to help them lead a healthy sex life. One hundred women participated in our study.
Results
The medium age for our patients was 52.24 years. In our population, 52% of the women underwent radical mastectomy. All of our patients underwent radiotherapy and 88% underwent chemotherapy. Before BC diagnosis, patients who rarely had sex represent 28% of the women, those who had sex once a week represent 52% and those who had sex on a regular basis (more than once a week) represented 20% of the population. After surgery, 72% of our patients reported rarely having sexual relationships (less than once a month). Only 16% of our patients reported having intercourse once a week. As for patients who maintained a regular sex life after surgery (more than once a week), they represent 12% of the population. This drop in the frequency of sexual relationship is linked to multiple causes: body dysmorphia and failure to accept body changes 76%, lower libido in 80%; less vaginal sensation in 64% and vaginal dryness in 84%. Dyspareunia was experienced by 60% compared 36% before surgery. None of the women sought medical consult. No medication nor lubrification was used by the patients to improve their symptoms.
Conclusions
Breast cancer survivors are reluctant to discuss their sexuality and the problems they are facing after surgery. Even though patients don’t ask for help, it is our duty as clinicians to identify the problems and help our patients to receive the adequate treatment and advice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1709P - Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Presenter: Deepak Kilari
Session: Poster session 11
1710P - Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Presenter: Benoit Blanchet
Session: Poster session 11
1711P - Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Presenter: John McGrane
Session: Poster session 11
1712P - Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13]
Presenter: Jwa Hoon Kim
Session: Poster session 11
1713P - A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
Presenter: Jue Hou
Session: Poster session 11
1714P - Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
Presenter: Simon Garinet
Session: Poster session 11
1715P - Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma
Presenter: Xu Zhang
Session: Poster session 11
1716P - Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
Presenter: martina catalano
Session: Poster session 11